Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

4NF5

Crystal structure of GluN1/GluN2A ligand-binding domain in complex with glycine and D-AP5

Summary for 4NF5
Entry DOI10.2210/pdb4nf5/pdb
Related4NF4 4NF6 4NF8
DescriptorGlutamate receptor ionotropic, NMDA 1, Glutamate receptor ionotropic, NMDA 2A, GLYCINE, ... (6 entities in total)
Functional Keywordsreceptor, glycine and d-ap5, transport protein
Biological sourceRattus norvegicus (rat)
More
Cellular locationCell membrane ; Multi-pass membrane protein : P35439 Q00959
Total number of polymer chains2
Total formula weight65673.81
Authors
Jespersen, A.,Tajima, N.,Furukawa, H. (deposition date: 2013-10-30, release date: 2014-03-12, Last modification date: 2024-10-30)
Primary citationJespersen, A.,Tajima, N.,Fernandez-Cuervo, G.,Garnier-Amblard, E.C.,Furukawa, H.
Structural Insights into Competitive Antagonism in NMDA Receptors.
Neuron, 81:366-378, 2014
Cited by
PubMed Abstract: There has been a great level of enthusiasm to downregulate overactive N-methyl-D-aspartate (NMDA) receptors to protect neurons from excitotoxicity. NMDA receptors play pivotal roles in basic brain development and functions as well as in neurological disorders and diseases. However, mechanistic understanding of antagonism in NMDA receptors is limited due to complete lack of antagonist-bound structures for the L-glutamate-binding GluN2 subunits. Here, we report the crystal structures of GluN1/GluN2A NMDA receptor ligand-binding domain (LBD) heterodimers in complex with GluN1- and GluN2-targeting antagonists. The crystal structures reveal that the antagonists, D-(-)-2-amino-5-phosphonopentanoic acid (D-AP5) and 1-(phenanthrene-2-carbonyl)piperazine-2,3-dicarboxylic acid (PPDA), have discrete binding modes and mechanisms for opening of the bilobed architecture of GluN2A LBD compared to the agonist-bound form. The current study shows distinct ways by which the conformations of NMDA receptor LBDs may be controlled and coupled to receptor inhibition and provides possible strategies to develop therapeutic compounds with higher subtype-specificity.
PubMed: 24462099
DOI: 10.1016/j.neuron.2013.11.033
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.903 Å)
Structure validation

243911

数据于2025-10-29公开中

PDB statisticsPDBj update infoContact PDBjnumon